These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 38663923)

  • 1. Use of GLP1 receptor agonists in early pregnancy and reproductive safety: a multicentre, observational, prospective cohort study based on the databases of six Teratology Information Services.
    Dao K; Shechtman S; Weber-Schoendorfer C; Diav-Citrin O; Murad RH; Berlin M; Hazan A; Richardson JL; Eleftheriou G; Rousson V; Diezi L; Haefliger D; Simões-Wüst AP; Addor MC; Baud D; Lamine F; Panchaud A; Buclin T; Girardin FR; Winterfeld U
    BMJ Open; 2024 Apr; 14(4):e083550. PubMed ID: 38663923
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bone fracture risk is not associated with the use of glucagon-like peptide-1 receptor agonists: a population-based cohort analysis.
    Driessen JH; Henry RM; van Onzenoort HA; Lalmohamed A; Burden AM; Prieto-Alhambra D; Neef C; Leufkens HG; de Vries F
    Calcif Tissue Int; 2015 Aug; 97(2):104-12. PubMed ID: 25894068
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pregnancy outcomes in women on metformin for diabetes or other indications among those seeking teratology information services.
    Panchaud A; Rousson V; Vial T; Bernard N; Baud D; Amar E; De Santis M; Pistelli A; Dautriche A; Beau-Salinas F; Cassina M; Dunstan H; Passier A; Kaplan YC; Duman MK; Maňáková E; Eleftheriou G; Klinger G; Winterfeld U; Rothuizen LE; Buclin T; Csajka C; Hernandez-Diaz S
    Br J Clin Pharmacol; 2018 Mar; 84(3):568-578. PubMed ID: 29215149
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-world effectiveness and safety of dapagliflozin therapy added to a GLP1 receptor agonist in patients with type 2 diabetes.
    Gorgojo-Martínez JJ; Serrano-Moreno C; Sanz-Velasco A; Feo-Ortega G; Almodóvar-Ruiz F
    Nutr Metab Cardiovasc Dis; 2017 Feb; 27(2):129-137. PubMed ID: 28077257
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risks of peri- and postoperative complications with glucagon-like peptide-1 receptor agonists.
    Klonoff DC; Kim SH; Galindo RJ; Joseph JI; Garrett V; Gombar S; Aaron RE; Tian T; Kerr D
    Diabetes Obes Metab; 2024 Aug; 26(8):3128-3136. PubMed ID: 38742898
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phenotype-based targeted treatment of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes.
    Cardoso P; Young KG; Nair ATN; Hopkins R; McGovern AP; Haider E; Karunaratne P; Donnelly L; Mateen BA; Sattar N; Holman RR; Bowden J; Hattersley AT; Pearson ER; Jones AG; Shields BM; McKinley TJ; Dennis JM;
    Diabetologia; 2024 May; 67(5):822-836. PubMed ID: 38388753
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is it Time to Expand Glucagon-like Peptide-1 Receptor Agonist Use for Weight Loss in Patients Without Diabetes?
    Updike WH; Pane O; Franks R; Saber F; Abdeen F; Balazy DD; Carris NW
    Drugs; 2021 Jun; 81(8):881-893. PubMed ID: 33929717
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heterogeneity of antidiabetic treatment effect on the risk of major adverse cardiovascular events in type 2 diabetes: a systematic review and meta-analysis.
    D'Andrea E; Kesselheim AS; Franklin JM; Jung EH; Hey SP; Patorno E
    Cardiovasc Diabetol; 2020 Sep; 19(1):154. PubMed ID: 32993654
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In-utero exposure to metformin for type 2 diabetes or polycystic ovary syndrome: A prospective comparative observational study.
    Diav-Citrin O; Steinmetz-Shoob S; Shechtman S; Ornoy A
    Reprod Toxicol; 2018 Sep; 80():85-91. PubMed ID: 29857030
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative effectiveness of SGLT2i versus GLP1-RA on cardiovascular outcomes in routine clinical practice.
    Fu EL; Clase CM; Janse RJ; Lindholm B; Dekker FW; Jardine MJ; Carrero JJ
    Int J Cardiol; 2022 Apr; 352():172-179. PubMed ID: 35074492
    [TBL] [Abstract][Full Text] [Related]  

  • 11. First-trimester exposure to metformin and risk of birth defects: a systematic review and meta-analysis.
    Cassina M; Donà M; Di Gianantonio E; Litta P; Clementi M
    Hum Reprod Update; 2014; 20(5):656-69. PubMed ID: 24861556
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pregnancy outcome following maternal exposure to statins: a multicentre prospective study.
    Winterfeld U; Allignol A; Panchaud A; Rothuizen LE; Merlob P; Cuppers-Maarschalkerweerd B; Vial T; Stephens S; Clementi M; De Santis M; Pistelli A; Berlin M; Eleftheriou G; Maňáková E; Buclin T
    BJOG; 2013 Mar; 120(4):463-71. PubMed ID: 23194157
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adherence to GLP1-RA and SGLT2-I affects clinical outcomes and costs in patients with type 2 diabetes.
    Ciardullo S; Savaré L; Rea F; Perseghin G; Corrao G
    Diabetes Metab Res Rev; 2024 May; 40(4):e3791. PubMed ID: 38549238
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparing medication persistence among patients with type 2 diabetes using sodium-glucose cotransporter 2 inhibitors or glucagon-like peptide-1 receptor agonists in real-world setting.
    Rea F; Ciardullo S; Savaré L; Perseghin G; Corrao G
    Diabetes Res Clin Pract; 2021 Oct; 180():109035. PubMed ID: 34487757
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The use of sodium-glucose co-transporter-2 inhibitors or glucagon-like peptide-1 receptor agonists versus sulfonylureas and the risk of lower limb amputations: a nation-wide cohort study.
    Werkman NCC; Driessen JHM; Stehouwer CDA; Vestergaard P; Schaper NC; van den Bergh JP; Nielen JTH
    Cardiovasc Diabetol; 2023 Jun; 22(1):160. PubMed ID: 37386427
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety of haloperidol and penfluridol in pregnancy: a multicenter, prospective, controlled study.
    Diav-Citrin O; Shechtman S; Ornoy S; Arnon J; Schaefer C; Garbis H; Clementi M; Ornoy A
    J Clin Psychiatry; 2005 Mar; 66(3):317-22. PubMed ID: 15766297
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus.
    Zelniker TA; Wiviott SD; Raz I; Im K; Goodrich EL; Furtado RHM; Bonaca MP; Mosenzon O; Kato ET; Cahn A; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Sabatine MS
    Circulation; 2019 Apr; 139(17):2022-2031. PubMed ID: 30786725
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Late-pregnancy dysglycemia in obese pregnancies after negative testing for gestational diabetes and risk of future childhood overweight: An interim analysis from a longitudinal mother-child cohort study.
    Gomes D; von Kries R; Delius M; Mansmann U; Nast M; Stubert M; Langhammer L; Haas NA; Netz H; Obermeier V; Kuhle S; Holdt LM; Teupser D; Hasbargen U; Roscher AA; Ensenauer R
    PLoS Med; 2018 Oct; 15(10):e1002681. PubMed ID: 30372451
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glucagon-like peptide 1 receptor agonists in patients with type 2 diabetes with and without chronic heart failure: A meta-analysis of randomized placebo-controlled outcome trials.
    Ferreira JP; Saraiva F; Sharma A; Vasques-Nóvoa F; Angélico-Gonçalves A; Leite AR; Borges-Canha M; Carvalho D; Packer M; Zannad F; Leite-Moreira A; Neves JS
    Diabetes Obes Metab; 2023 Jun; 25(6):1495-1502. PubMed ID: 36722252
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glucagon-like peptide 1 receptor agonist use and risk of thyroid cancer: Scandinavian cohort study.
    Pasternak B; Wintzell V; Hviid A; Eliasson B; Gudbjörnsdottir S; Jonasson C; Hveem K; Svanström H; Melbye M; Ueda P
    BMJ; 2024 Apr; 385():e078225. PubMed ID: 38683947
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.